GF Fund Management CO. LTD. Invests $445,000 in Illumina, Inc. (NASDAQ:ILMN)

GF Fund Management CO. LTD. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 3,330 shares of the life sciences company's stock, valued at approximately $445,000.

Several other large investors also recently bought and sold shares of ILMN. Bank of Stockton boosted its holdings in shares of Illumina by 3.8% during the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company's stock worth $289,000 after purchasing an additional 80 shares during the last quarter. Stephens Inc. AR lifted its holdings in Illumina by 1.4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company's stock valued at $885,000 after acquiring an additional 90 shares during the last quarter. Spire Wealth Management lifted its holdings in Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company's stock valued at $63,000 after acquiring an additional 97 shares during the last quarter. IFP Advisors Inc lifted its holdings in Illumina by 19.1% in the fourth quarter. IFP Advisors Inc now owns 617 shares of the life sciences company's stock valued at $82,000 after acquiring an additional 99 shares during the last quarter. Finally, Freedom Investment Management Inc. lifted its holdings in Illumina by 3.7% in the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock valued at $382,000 after acquiring an additional 101 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of NASDAQ ILMN traded down $2.89 during midday trading on Friday, reaching $81.39. 827,144 shares of the company were exchanged, compared to its average volume of 2,420,972. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The stock has a fifty day simple moving average of $77.86 and a 200 day simple moving average of $107.09. The stock has a market cap of $12.88 billion, a P/E ratio of -10.60, a PEG ratio of 1.60 and a beta of 1.35.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the company posted $0.98 earnings per share. The business's revenue was down 1.4% on a year-over-year basis. On average, research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ILMN. Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Robert W. Baird decreased their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 5th. HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. Piper Sandler decreased their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Finally, Barclays decreased their price target on Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $128.15.

Insider Activity at Illumina

In other news, CFO Ankur Dhingra acquired 6,100 shares of Illumina stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer now directly owns 24,906 shares in the company, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.60% of the stock is owned by insiders.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.